A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here
Friday, 27 June 2008
The European Commission has closely examined Turkey's general state of preparedness in IP. Taking into account Turkey's present state of preparations, and in line with the Council conclusions on 11 December 2006, the EU emphasised that Turkey must complete its alignment with the Community acquis concerning Community-wide exhaustion of rights and the introduction of supplementary protection certificates, ensuring that these rights will be implemented by the date of accession [source: ABHaber.com]
Thursday, 26 June 2008
Wednesday, 25 June 2008
House Judiciary Committee Chairman John Conyers Jr. has explained that
“this small but important change simply gives the [United States Patent and Trademark Office] discretion to accept a late application, within a limited time period, under specific conditions. This change is both good patent policy and good for public health.”The language of the proposed legislation specifically restricts one subsection to “a drug intended for use in humans that is in the anticoagulant class of drugs”, the class of products to which Angiomax belongs.
The change has yet to be considered by the Senate, and Citizens Against Government Waste have denounced the bill.
Tuesday, 24 June 2008
Thursday, 19 June 2008
If you'd like to know more about us, or would like to contribute material to The SPC Blog, please email any of the contributors whose names (linked to their relevant coordinates) appear in the box which you will find in the box near the top of the side panel to your left.
* patent owners who feel they cannot obtain a reasonable benefit from the patent grant on account of the lengthy regulatory procedures that require compliance before pharma and agrichemical products can be marketed,
* investors who may be reluctant to fund research and development if the prospect of a good commercial return is lacking,
* manufacturers and distributors of generic products, who are excluded from the market by the extension of patent grants,
* public sector purchasers of products, whose budgets may be restricted and subject to conditions unrelated to market forces,
* consumers whose access to products may be reduced or less affordable for as long as patent protection remains,
* national and regional competition authorities, which bear responsibility for ensuring that patent monopolies are not the basis for abuse of a dominant position.